http://www.cambridge-news.co.uk/Quic...ail/story.html
This is but one example of what Snapiti has been alerting to in the bladder cancer urine testing space - it is getting crowded. Many fizzes out to oblivion but some are being brought to market.
Those who are funding these developments are not mugs and as part of their due diligence, are certainly aware of the CxBladders in this world.
I have often wondered if I am missing something when I see yet another company entering the space. Afterall, PEB already boasts of such a superior product that it must be sheer foolery to invest in anything else.
This is where it is important to dig deeper into the tests being developed and compare the mechanics of how the tests are being brought to market, and critically, at what price.
And be ever cynical and questioning of company's assertions.